Expanded studies of piperacillin/tazobactam formulations: variations among branded product lots and assessment of 46 generic lots

Diagnostic Microbiology and Infectious Disease

Volumn 65, Issue 3, 2009, Pages 319-322

  Moet, Gary J ^a   Watters, Amy A ^a   Sader, Helio S ^a,b   Jones, Ronald N ^a,c  

^a JMI LABORATORIES   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Generic potencies; MIC assays; Piperacillin tazobactam; Zosyn

Indexed keywords

DBL; GENERIC DRUG; IBIGEN; PIPERACILLIN PLUS TAZOBACTAM; TASOVAK; TAZPEN; UNCLASSIFIED DRUG; VITALIS; ZOPERCIN;

ARTICLE; CHEMICAL ANALYSIS; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DETERMINATION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG POTENCY; DRUG QUALITY; IN VITRO STUDY; PRIORITY JOURNAL; QUALITY CONTROL; STANDARD;

ANTI-BACTERIAL AGENTS; BACTERIA; DRUGS, GENERIC; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PIPERACILLIN;

EID: 71749086131     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2009.06.012     Document Type: Article

References (19)

1. Bradford P.A., and Sanders C.C. Use of a predictor panel to evaluate susceptibility test methods proposed for piperacillin-tazobactam. Antimicrob. Agents Chemother. 37 (1993) 2578-2583
2. Clinical and Laboratory Standards Institute (CLSI). M07-A8. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 8th ed. (2009), CLSI, Wayne, PA
3. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: 19th information supplement (M100-S19) (2009), CLSI, Wayne, PA
4. Fujimura S., Watanabe A., Fuse K., Kikuchi T., Gomi K., and Tokue Y. In vitro susceptibility of clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) to manufactured generic drugs compared with the brand vancomycin. Int. J. Antimicrob. Agents 31 (2008) 391-392
5. Jones R.N., and Barry A.L. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830). Diagn. Microbiol. Infect. Dis. 12 (1989) 495-510
6. Jones R.N., Fritsche T.R., and Moet G.J. In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn®, Wyeth) formulation. Diagn. Microbiol. Infect. Dis. 61 (2008) 76-79
7. Jones R.N., Sader H.S., Stillwell M.G., and Rhomberg P.R. Anti-pseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007). ECCMID, May 16-19, 2009. Helsinki, Finland (2009) (Abstr. P679)
8. Jones R.N., Watters A.A., Sader H.S., and Moet G.J. Extended studies of Piperacillin/tazobactam generic formulations: 20 variations of branded product lots and assessment of 38 generic lots. ECCMID, May 16-19, 2009. Helsinki, Finland (2009) (Abstr R2094)
9. Kaye D. Importation of foreign-made drugs: are we getting what we expect (editors comment). Clin. Infect. Dis. 46 (2008) iii
10. Kuck N.A., Petersen P.J., Weiss W.J., Jacobus N.V., Testa R.T., and Tally F.P. Synergistic activity of piperacillin: YTR-830H combinations in vitro and in vivo. J. Chemother. 1 (1989) 105-106
11. Lambert P.A., and Conway B.R. Pharmaceutical quality of ceftriaxone generic drug products compared with Rocephin. J. Chemother. 15 (2003) 357-368
12. Neu H.C. The role of β-lactamase inhibitors in chemotherapy. Pharmacol. Ther. 30 (1985) 1-18
13. Package Insert. Package I (2007), Philadelphia, PA, Wyeth Pharmaceuticals Inc. http://www.zosyn.com Revised November 2007
14. Pasqualotto A.C., and Denning D.W. Generic substitution of itraconazole resulting in sub-therapeutic levels and resistance. Int. J. Antimicrob. Agents. 30 (2007) 93-94
15. Rodriguez C.A., Zuluaga A.F., Salazar B.E., Agudelo M., and Vesga M. Experimental comparison of 11 generic products (GP) of oxacillin (OXA) with the original compound (OC) in terms of concentration of active principle (CAP), in vitro activity, and in vivo efficacy, using the neutropenic murine thigh infection model (NMTIM). 44th ICAAC, October 29-November 2, 2004. Washington, D.C., USA (2004) (Abstr. A-1305)
16. Schito G.C., and Keenan M.H. Predicting the clinical efficacy of generic formulations of ceftriaxone. J. Chemother. 17 Suppl 2 (2005) 33-40
17. Wetterich U., and Mutschler E. Quality of cefotaxime sodium preparations. Arzneimittelforschung 45 (1995) 74-80
18. Ye Y., Lee J., Chen Y., Lin S.W., and Chien S. A comparative study of the clinical efficacy of two piperacillin/tazobactam products. Annual Conference of Taiwan Society of Health System Pharmacists. Taiwan. Poster 27 (2006)
19. Zuluaga A.F., Salazar B.E., Loaiza S.A., Agudelo M., and Vesga M. Therapeutic equivalence (TE) with the original compound (OC) of 8 genetic products (GP) of ampicillin (AMP) determined in the neutropenic murine thigh infection model (NMTIM). 44th ICAAC, October 29-November 2, 2004. Washington, D.C. (2004) (Abstr. E-2033)